13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q1 2023 · Filed February 8, 2023 · Accession 0001910264-23-000001
Total Value
$273.9M
Positions
5
Other Managers
0
Confidential Omitted
No
Holdings (5)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | ARCELLX INC. | ACLX | 5,500,007 | $170.4M | 62.20% |
| 2 | DESIGN THERAPEUTICS INC | DSGN | 6,526,476 | $67.0M | 24.44% |
| 3 | ARS PHARMACEUTICALS | SPRY | 3,009,677 | $25.7M | 9.37% |
| 4 | NKARTA INC. | NKTX | 1,333,333 | $8.0M | 2.92% |
| 5 | EFFECTOR THERAPEUTICS INC | 28202V108 | 6,822,114 | $2.9M | 1.07% |